Shares in Australian biopharmaceutical company Mesoblast jumped as much as 25 per cent after the US Food and Drug Administration recognised its cell therapy, Revascor, as a potential breakthrough treatment for heart disease in newborn babies.
Joanna Mather joined the AFR as an education reporter in 2008. She spent four years in the Canberra press gallery before becoming superannuation reporter in 2016, deputy news director in 2021 and wealth editor in 2023. Connect with Joanna on Twitter. Email Joanna at jmather@afr.com
